{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:37:02Z","timestamp":1781077022091,"version":"3.54.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006733","name":"Indiana University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.drup.2025.101298","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:37:40Z","timestamp":1757349460000},"page":"101298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Overcoming multidrug resistance using small molecule dynamic inhibitors by hijacking nascent and inducing turnover of mature ABCG2 for degradation in lysosomes"],"prefix":"10.1016","volume":"84","author":[{"given":"Zizheng","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuzhen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7953-179X","authenticated-orcid":false,"given":"JoAnne J","family":"Babula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2803-9914","authenticated-orcid":false,"given":"Jian-Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2025.101298_bib1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1124\/jpet.119.258392","article-title":"CC-115, a dual mammalian target of Rapamycin\/DNA-Dependent protein kinase inhibitor in clinical trial, is a substrate of ATP-Binding cassette G2, a risk factor for CC-115 resistance","volume":"371","author":"Beebe","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drup.2025.101298_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drup.2025.101298_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0014-5793(96)00517-0","article-title":"Dynamin and receptor-mediated endocytosis","volume":"389","author":"Damke","year":"1996","journal-title":"FEBS Lett."},{"key":"10.1016\/j.drup.2025.101298_bib4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1083\/jcb.127.4.915","article-title":"Induction of mutant dynamin specifically blocks endocytic coated vesicle formation","volume":"127","author":"Damke","year":"1994","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.drup.2025.101298_bib5","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2025.101298_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2023.03.003","article-title":"Targeted protein degrader development for cancer: advances, challenges, and opportunities","volume":"44","author":"Fang","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drup.2025.101298_bib7","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1110\/ps.9.9.1753","article-title":"Modeling of loops in protein structures","volume":"9","author":"Fiser","year":"2000","journal-title":"Protein Sci."},{"key":"10.1016\/j.drup.2025.101298_bib8","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/1535-7163.MCT-07-0352","article-title":"New inhibitors of ABCG2 identified by high-throughput screening","volume":"6","author":"Henrich","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2025.101298_bib9","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/0008-5472.CAN-03-3344","article-title":"Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro","volume":"64","author":"Houghton","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2025.101298_bib10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/onc.2015.215","article-title":"Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo","volume":"35","author":"Huang","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2025.101298_bib11","doi-asserted-by":"crossref","first-page":"R444","DOI":"10.1186\/bcr1026","article-title":"Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice","volume":"7","author":"Jenkins","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.drup.2025.101298_bib12","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1158\/0008-5472.CAN-05-3801","article-title":"Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2025.101298_bib13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0003-2697(89)90115-2","article-title":"Jr., characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases","volume":"180","author":"Maley","year":"1989","journal-title":"Anal. Biochem"},{"key":"10.1016\/j.drup.2025.101298_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1126\/scitranslmed.3000237","article-title":"Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population","volume":"1","author":"Matsuo","year":"2009","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drup.2025.101298_bib15","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1021\/bi300301a","article-title":"Different roles of TM5, TM6, and ECL3 in the oligomerization and function of human ABCG2","volume":"51","author":"Mo","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.drup.2025.101298_bib16","first-page":"1","article-title":"Human ABCG2: structure, function, and its role in multidrug resistance","volume":"3","author":"Mo","year":"2012","journal-title":"Int. J. Biochem. Mol. Biol."},{"key":"10.1016\/j.drup.2025.101298_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.drup.2005.02.002","article-title":"Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters","volume":"8","author":"Ozvegy-Laczka","year":"2005","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2025.101298_bib18","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1124\/mol.65.6.1485","article-title":"High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter","volume":"65","author":"Ozvegy-Laczka","year":"2004","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drup.2025.101298_bib19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1073\/pnas.73.4.1255","article-title":"Clathrin: a unique protein associated with intracellular transfer of membrane by coated vesicles","volume":"73","author":"Pearse","year":"1976","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2025.101298_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005676","article-title":"A novel two Mode-Acting inhibitor of ABCG2-Mediated multidrug transport and resistance in cancer chemotherapy","volume":"4","author":"Peng","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2025.101298_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015276","article-title":"Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells","volume":"5","author":"Peng","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2025.101298_bib22","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.drup.2025.101298_bib23","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1158\/0008-5472.CAN-15-1874","article-title":"Effective targeting of the survivin dimerization interface with Small-Molecule inhibitors","volume":"76","author":"Qi","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2025.101298_bib24","first-page":"5850","article-title":"Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin c","volume":"58","author":"Rabindran","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2025.101298_bib25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2174\/138920111795163913","article-title":"The challenge of exploiting ABCG2 in the clinic","volume":"12","author":"Robey","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.drup.2025.101298_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2008.11.003","article-title":"ABCG2: a perspective","volume":"61","author":"Robey","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drup.2025.101298_bib27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/acsptsci.2c00142","article-title":"Proteolysis targeting chimeras (PROTACs): a perspective on integral membrane protein degradation","volume":"5","author":"Ruffilli","year":"2022","journal-title":"ACS Pharm. Transl. Sci."},{"key":"10.1016\/j.drup.2025.101298_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nchembio.144","article-title":"Golgicide a reveals essential roles for GBF1 in Golgi assembly and function","volume":"5","author":"Saenz","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.drup.2025.101298_bib29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1021\/acs.biochem.2c00245","article-title":"Molecular glues: the adhesive connecting targeted protein degradation to the clinic","volume":"62","author":"Sasso","year":"2023","journal-title":"Biochemistry"},{"key":"10.1016\/j.drup.2025.101298_bib30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/mol.113.088609","article-title":"Molecular pharmacology of ABCG2 and its role in chemoresistance","volume":"84","author":"Stacy","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drup.2025.101298_bib31","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1158\/1535-7163.MCT-12-0215","article-title":"New use for an old drug: inhibiting ABCG2 with sorafenib","volume":"11","author":"Wei","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2025.101298_bib32","doi-asserted-by":"crossref","first-page":"10338","DOI":"10.1073\/pnas.0901249106","article-title":"Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout","volume":"106","author":"Woodward","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2025.101298_bib33","doi-asserted-by":"crossref","first-page":"19781","DOI":"10.1074\/jbc.M310785200","article-title":"Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2","volume":"279","author":"Xu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2025.101298_bib34","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1158\/0008-5472.CAN-06-3169","article-title":"Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity","volume":"67","author":"Xu","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2025.101298_bib35","doi-asserted-by":"crossref","first-page":"44268","DOI":"10.1074\/jbc.M207003200","article-title":"Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1","volume":"277","author":"Yang","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2025.101298_bib36","doi-asserted-by":"crossref","first-page":"20222","DOI":"10.1074\/jbc.RA119.008347","article-title":"Single-nucleotide polymorphisms in a short basic motif in the ABC transporter ABCG2 disable its trafficking out of endoplasmic reticulum and reduce cell resistance to anticancer drugs","volume":"294","author":"Zhang","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2025.101298_bib37","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Tar."},{"key":"10.1016\/j.drup.2025.101298_bib38","doi-asserted-by":"crossref","first-page":"12339","DOI":"10.1073\/pnas.192276999","article-title":"Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo","volume":"99","author":"Zhou","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764625001013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764625001013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T23:40:25Z","timestamp":1765150825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764625001013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"alternative-id":["S1368764625001013"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2025.101298","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming multidrug resistance using small molecule dynamic inhibitors by hijacking nascent and inducing turnover of mature ABCG2 for degradation in lysosomes","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2025.101298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101298"}}